Curasight (CURAS) Stock Overview
Develops therapeutic and diagnostic solutions for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CURAS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Curasight A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 15.95 |
| 52 Week High | DKK 17.85 |
| 52 Week Low | DKK 1.80 |
| Beta | 0.26 |
| 1 Month Change | -2.74% |
| 3 Month Change | 42.41% |
| 1 Year Change | 105.54% |
| 3 Year Change | -8.23% |
| 5 Year Change | -48.13% |
| Change since IPO | -21.43% |
Recent News & Updates
Shareholder Returns
| CURAS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.9% | -4.1% | -5.1% |
| 1Y | 105.5% | 7.6% | 2.8% |
Return vs Industry: CURAS exceeded the Swedish Biotechs industry which returned 7.6% over the past year.
Return vs Market: CURAS exceeded the Swedish Market which returned 2.8% over the past year.
Price Volatility
| CURAS volatility | |
|---|---|
| CURAS Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CURAS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CURAS's weekly volatility has decreased from 19% to 13% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 4 | Ulrich Krasilnikoff | www.curasight.com |
Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. The company develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. It is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in Phase II clinical trials to treat non-small cell lung cancer.
Curasight A/S Fundamentals Summary
| CURAS fundamental statistics | |
|---|---|
| Market cap | DKK 764.37m |
| Earnings (TTM) | -DKK 53.23m |
| Revenue (TTM) | n/a |
Is CURAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURAS income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 49.68m |
| Gross Profit | -DKK 49.68m |
| Other Expenses | DKK 3.55m |
| Earnings | -DKK 53.23m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 28, 2026
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 139.7% |
How did CURAS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 23:36 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curasight A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.